secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGENUS INC (AGEN)
CIK:        0001098972
Form:       8-K
Filed at:   2024-08-02T23:59:59+00:00
Accession:  0000950170-24-089932
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

BMS terminates AGEN1777 license; Agenus regains rights to TIGIT bispecific antibody
--------------------------------------------------------------------------------

- BMS voluntarily terminates AGEN1777 license agreement effective Jan 26, 2025, as part of strategic pipeline realignment.
- Agenus received $200M upfront plus $20M (Phase 1) and $25M (Phase 2) milestone payments from BMS since 2021.
- No early termination penalties; Agenus gets exclusive, royalty-free license to BMS know-how and patent rights for AGEN1777.
- BMS will assign all regulatory registrations and approvals for AGEN1777 back to Agenus.
- Agenus plans to explore further development or relicensing of AGEN1777, now with safety and clinical activity data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1098972/000095017024089932/0000950170-24-089932-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1098972/000095017024089932/agen-20240730.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-089932

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer